Filtered By:
Cancer: Cancer
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 426956 results found since Jan 2013.
Glioma Response to IDH Inhibition: Real-World Experience
Clin Cancer Res. 2023 Sep 22. doi: 10.1158/1078-0432.CCR-23-2164. Online ahead of print.ABSTRACTTreatment of IDH mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. IDH inhibition has a therapeutic benefit in patients with these tumors.PMID:37738033 | DOI:10.1158/1078-0432.CCR-23-2164
Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Rimas V Lukas Craig Horbinski Source Type: research
Genetic Predictors of Ibrutinib-Related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia
CONCLUSIONS: Our findings suggest possible genetic determinants of ibrutinib-related CVSEs in CLL. If replicated in a larger study, pre-treatment pharmacogenetic testing for GATA4 and KCNQ1 polymorphisms may be a useful clinical tool for personalizing treatment selection for CLL and/or instituting early risk-mitigation strategies.PMID:37738027 | DOI:10.1158/1078-0432.CCR-23-0421
Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Issam S Hamadeh Jai N Patel Ryan Jacobs Hang Zeng Jiaxian He Bei Hu Tamara Kay Moyo Amy Soni Steven Park Ed Copelan Belinda Avalos Alicia Hamilton Nury Steuerwald Nilanjan Ghosh Source Type: research
Harnessing Dendritic Cells: Next Frontier for Durable Immune Control in Myeloma
Clin Cancer Res. 2023 Sep 22:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-2292. Online ahead of print.ABSTRACTImmune-based approaches including T-cell redirection have transformed the therapeutic landscape in myeloma. Injection of dendritic cells (DC) led to the induction of immune responses in vaccinated patients with myeloma. These studies pave the way for future combination strategies harnessing DCs to enhance tumor immunity and improve outcomes in myeloma. See related article by Freeman et al., p. 000.PMID:37737650 | DOI:10.1158/1078-0432.CCR-23-2292
Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Madhav V Dhodapkar Source Type: research
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
CONCLUSIONS: Two doses of DC:Ad-S, one given immediately before and another after ASCT, were feasible and safe. A high frequency of vaccine-specific immune responses was seen in combination with durable clinical outcomes, supporting ongoing investigation into the potential of this approach.PMID:37735756 | DOI:10.1158/1078-0432.CCR-22-3987
Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Ciara L Freeman Reginald Atkins Indumathy Varadarajan Meghan Menges Jeffrey Edelman Rachid Baz Jason Brayer Omar Castaneda Puglianini Jose Leonel Ochoa-Bayona Taiga Nishihori Kenneth H Shain Bijal Shah Dung Tsa Chen Linda Kelley Domenico Coppola Melissa A Source Type: research
Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
CONCLUSION: The risk score model was effective for predicting both prognosis and sensitivity to therapeutic drugs, suggesting its possible usefulness for the management of patients with breast cancer.PMID:37736788 | DOI:10.1007/s00432-023-05372-z
Source: Clinical Breast Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Shuyan Liu Yiwen Zheng Shujin Li Yaoqiang Du Xiaozhen Liu Hongchao Tang Xuli Meng Qinghui Zheng Source Type: research
Proteus mirabilis: A rare cause of pneumonia, radiologically mimicking malignancy of the lung
CONCLUSION: Mass lesions suspected for malignancy should be managed with involvement of multiple medical disciplines, to ensure correct and timely diagnosis. This is to avoid miss-management.PMID:37736480 | PMC:PMC10509339 | DOI:10.1002/ccr3.7937
Source: Clinical Lung Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Saif Ullah Ramin Saadaat Hidayatullah Hamidi Ahmed Maseh Haidary Source Type: research
Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets
CONCLUSION: This review summarises important predictive ncRNA biomarkers that were reported in cancer patients treated with different immunotherapeutic modalities, including monoclonal antibodies, small molecule inhibitors, cancer vaccines and CAR-T cells. In addition, a concise discussion on forthcoming perspectives is provided, outlining technical approaches for the optimal utilisation of immunomodulatory ncRNA biomarkers as predictive tools and therapeutic targets.PMID:37735815 | DOI:10.1002/ctm2.1425
Source: Clinical Lung Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Murad Alahdal Eyad Elkord Source Type: research
The Lysosomal Calcium Channel TRPML1 Maintains Mitochondrial Fitness in NK Cells through Interorganelle Cross-Talk
In this study, we examined the role of TRPML1 (TRP cation channel, mucolipin subfamily, member 1) in regulating the homeostasis of secretory lysosomes and their cross-talk with mitochondria in human NK cells. We found that genetic deletion of TRPML1, which localizes to lysosomes in NK cells, led to mitochondrial fragmentation with evidence of collapsed mitochondrial cristae. Consequently, TRPML1-/- NK92 (NK92ML1-/-) displayed loss of mitochondrial membrane potential, increased reactive oxygen species stress, reduced ATP production, and compromised respiratory capacity. Using sensitive organelle-specific probes, we observed...
Source: Journal of Immunology - September 22, 2023 Category: Allergy & Immunology Authors: Dennis Clement Edina K Szabo Silje Zandstra Krokeide Merete Thune Wiiger Marianna Vincenti Daniel Palacios Young-Tae Chang Christian Grimm Sandip Patel Harald Stenmark Andreas Brech Rakesh Kumar Majhi Karl-Johan Malmberg Source Type: research
Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma
Oncologist. 2023 Sep 20:oyad263. doi: 10.1093/oncolo/oyad263. Online ahead of print.ABSTRACTAppendiceal cancer is a rare, orphan disease with no therapies currently approved by the FDA for its treatment. Given the limited data regarding drug efficacy, these tumors have historically been treated with chemotherapy designed for colon cancer. However, an overwhelming body of molecular data has demonstrated that appendiceal adenocarcinoma is a distinct entity with key molecular differences from colon cancer, notably rare APC mutation. Recognizing that APC loss-of-function is thought to contribute to taxane resistance and that t...
Source: The Oncologist - September 22, 2023 Category: Cancer & Oncology Authors: Julia Dansby Aditya More Mohammad Zeineddine Abdelrahman Yousef Alisha Bent Farshid Dayyani Robert Wolff Michael Overman John Paul Shen Source Type: research
Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
CONCLUSION: The risk score model was effective for predicting both prognosis and sensitivity to therapeutic drugs, suggesting its possible usefulness for the management of patients with breast cancer.PMID:37736788 | DOI:10.1007/s00432-023-05372-z
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Shuyan Liu Yiwen Zheng Shujin Li Yaoqiang Du Xiaozhen Liu Hongchao Tang Xuli Meng Qinghui Zheng Source Type: research
FBXW2 suppresses breast tumorigenesis by targeting AKT-Moesin-SKP2 axis
In this study, we identified positive as well as negative regulators of Moesin. Our study reveals that Moesin is a cellular target of F-box protein FBXW2. We showed that FBXW2 suppresses breast cancer progression through directing proteasomal degradation of Moesin. In contrast, AKT kinase plays an important role in oncogenic function of Moesin by protecting it from FBXW2-mediated proteasomal degradation. Mechanistically, AKT phosphorylates Moesin at Thr-558 and thereby prevents its degradation by FBXW2 via weakening the association between FBXW2 and Moesin. Further, accumulated Moesin prevents FBXW2-mediated degradation of...
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Ganesh Kumar Barik Osheen Sahay Anindya Mukhopadhyay Rajesh Kumar Manne Sehbanul Islam Anup Roy Somsubhra Nath Manas Kumar Santra Source Type: research
Therapeutic benefits of prophetic medicine remedies in treating hematological diseases (A review article)
Am J Blood Res. 2023 Aug 15;13(4):130-142. eCollection 2023.ABSTRACTHematological disorders are common medical ailments constituting an important cause of morbidity and mortality worldwide, which may be managed efficiently using different prophetic medicine remedies as adjuvants to current therapeutics. Prophetic medicine includes the body of knowledge about medicine that has been derived from the deeds, customs (sunnah), ahadith (sayings), actions, and agreements of Prophet Muhammad, peace be upon him. This review article aims at exploring the magnitude of therapeutic benefits of prophetic medicine remedies as adjuvant tr...
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Ghazi H Mogharbel Ahmad S Badawi Amal Yaseen Zaman Mehrevan M Abd Elmoniem Ibrahim M Abdel-Rahman Mariam Eid Alenazi Fareed Akbar Shah Mohamed Abdelnaem Aly Syed Nazar Imam Nusaybah Eid Alenazi Salah Mohamed El Sayed Source Type: research
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
CONCLUSIONS: Two doses of DC:Ad-S, one given immediately before and another after ASCT, were feasible and safe. A high frequency of vaccine-specific immune responses was seen in combination with durable clinical outcomes, supporting ongoing investigation into the potential of this approach.PMID:37735756 | DOI:10.1158/1078-0432.CCR-22-3987
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Ciara L Freeman Reginald Atkins Indumathy Varadarajan Meghan Menges Jeffrey Edelman Rachid Baz Jason Brayer Omar Castaneda Puglianini Jose Leonel Ochoa-Bayona Taiga Nishihori Kenneth H Shain Bijal Shah Dung Tsa Chen Linda Kelley Domenico Coppola Melissa A Source Type: research
CYFIP2 serves as a prognostic biomarker and correlates with tumor immune microenvironment in human cancers
CONCLUSION: Our results suggested that CYFIP2 may serve as a prognostic cancer biomarker for determining prognosis and might be a promising therapeutic strategy for tumor immunotherapy.PMID:37735711 | DOI:10.1186/s40001-023-01366-2
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Qiliang Peng Bixin Ren Kedao Xin Weihui Liu Md Shahin Alam Yinyin Yang Xuhao Gu Yaqun Zhu Ye Tian Source Type: research
Different states of stemness of glioblastoma stem cells sustain glioblastoma subtypes indicating novel clinical biomarkers and high-efficacy customized therapies
CONCLUSIONS: In this study we report that an inherent enrichment of distinct GSCs pools underpin the functional inter-cluster variances displayed by GBM patients. We uncover two selectively represented novel functional biomarkers capable of discriminating GBM patients' stratification, survival and drug response, setting the stage for the determination of patient-tailored diagnostic and prognostic strategies and, mostly, for the design of appropriate, patient-selective treatment protocols.PMID:37735434 | DOI:10.1186/s13046-023-02811-0
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Alberto Visioli Nadia Trivieri Gandino Mencarelli Fabrizio Giani Massimiliano Copetti Orazio Palumbo Riccardo Pracella Maria Grazia Cariglia Chiara Barile Luigi Mischitelli Amata Amy Soriano Pietro Palumbo Federico Legnani Francesco DiMeco Leonardo Gorgog Source Type: research
